2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
July 10, 2018
Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806
July 9, 2018
Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day
June 29, 2018
FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
June 15, 2018
Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association
June 14, 2018
Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China
June 5, 2018
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
June 4, 2018
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253
May 31, 2018
APTOSE Enters into US$20 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC
May 17, 2018
Aptose to Present New CG’806 Data at the 23rd Congress of the European Hematology Association
May 10, 2018
Aptose Reports Results for the First Quarter Ended March 31, 2018
May 7, 2018
Aptose Exercises Early Option for CG-806 License From CrystalGenomics
May 1, 2018
Aptose To Release First Quarter Ended March 31, 2018 Financial Results and Hold Conference Call on May 10, 2018
April 25, 2018
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors
April 24, 2018
Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2018
April 17, 2018
Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting
April 16, 2018
OHSU and Aptose Present New CG’806 Preclinical Data at 2018 AACR Annual Meeting
April 16, 2018
Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting
April 3, 2018
Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
March 28, 2018
Aptose Biosciences Establishes New At-the-Market Facility
March 27, 2018
Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017
March 15, 2018
Aptose to Present New CG’806 and APTO-253 Data at the 2018 AACR Annual Meeting
March 8, 2018
Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018
March 7, 2018
Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
March 6, 2018
Aptose to Participate in Upcoming Investor Conferences In March 2018
February 7, 2018
Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus
January 2, 2018
Aptose Biosciences to Present at Biotech Showcase™ 2018 Conference